A Phase 1b Study of JNJ-79635322 in Combination With Daratumumab or Pomalidomide for Multiple Myeloma
Latest Information Update: 06 Feb 2025
Price :
$35 *
At a glance
- Drugs JNJ 79635322 (Primary) ; Daratumumab; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 16 Jan 2025 New trial record